The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 50 sources its claims cite were checked for support.
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells
Open accessAbstract
BACKGROUND AND PURPOSE: In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412. To date, no unequivocal explanation for the failure of TGN1412 to stimulate profound cytokine release in vitro or in vivo in species used for pre-clinical safety testing has been established. Here, we have identified a species difference almost certainly responsible for this disparate immunopharmacology. EXPERIMENTAL APPROACH: Polychromatic flow cytometry and intracellular cytokine staining were employed to dissect the in vitro immunopharmacology of TGN1412 and other therapeutic mAbs at the cellular level to identify differences between humans and species used for pre-clinical safety testing. KEY RESULTS: In vitro IL-2 and IFN-γ release from CD4+ effector memory T-cells were key indicators of a TGN1412-type response. This mechanism of cytokine release differed from that of other therapeutic mAbs, which can cause adverse reactions, because these other mAbs stimulate cytokine release primarily from natural killer cells. In contrast to humans, CD28 is not expressed on the CD4+ effector memory T-cells of all species used for pre-clinical safety testing, so cannot be stimulated by TGN1412. CONCLUSIONS AND IMPLICATIONS: It is likely that activation of CD4+ effector memory T-cells by TGN1412 was responsible for the cytokine storm. Lack of CD28 expression on the CD4+ effector memory T-cells of species used for pre-clinical safety testing of TGN1412 offers an explanation for the failure to predict a 'cytokine storm' in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Own result · 25 Own interpretation · 7 Partly supported · 5 Supported so far · 5 Sources not found · 5 No full text of the sources · 4 Supported · 4 Not checked yet · 3 No basis given · 1 Not supported · 1 Own method · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Effector memory CD4 + T-cells lacking CD28 expression have been reported in humans, but only in association with autoimmune diseases such as rheumatoid arthritis, Crohn's disease or multiple sclerosis (Markovic-Plese et al., 2001;Fasth et al., 2004;Garcia de Tena et al., 2004), and were not observed with the healthy donors used in this study.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not matchedcites Markovic-Plese et al., 2001
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites Fasth et al., 2004 sourceExperimental — accuracy not yet measured
The Introduction (page not specified) says CD28-negative CD4+ T cells have been described in healthy elderly adults as well as patients with inflammatory conditions. The paper studies these cells as an effector-memory population in rheumatoid arthritis, but it does not support—and its Introduction contradicts—the claim that they have been reported only in association with autoimmune disease. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites Garcia de Tena et al., 2004 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Importantly, IFN-g expression is largely limited to the CD4 + effector memory T-cells (Sallusto et al., 1999;Amyes et al., 2005).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Sallusto et al., 1999 source
- Supportedcites Amyes et al., 2005 source
In the section on virus-specific CD4+ T-cell subsets, the paper says IFN-γ expression was usually associated with a CCR7− phenotype. The paper identifies CCR7− antigen-experienced cells as effector memory cells, supporting the claim’s qualified wording, “largely limited.” (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Differences in the proportions of CD4 + effector memory T-cells producing TNF-a, IL-2 and IFN-g combinations following TGN1412 stimulation may reflect the heterogeneous nature of this population which contains multiple functional subsets with different cytokine repertoires (e.g.Th1, Th2, Th9, Th17 and Th22) (Annunziato and Romagnani, 2009;Sallusto and Lanzavecchia, 2009).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, these findings demonstrate that the in vitro safety procedures described by Stebbings et al. (2007) are applicable to other therapeutic mAbs, if IL-2 and IFN-g release are used as biomarkers for a TGN1412-type adverse response.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Supportedcites Stebbings et al. (2007) source
The methods section describes Stebbings et al.’s in vitro procedures, including measurement of IL-2 and IFN-γ release. The Dose responses to TGN1412 section reports release of both cytokines from human lymphocytes exposed to immobilized TGN1412. The conclusion that those procedures apply to other therapeutic mAbs is presented as the citing authors’ finding, not as a result attributed to Stebbings et al.; page numbers were unavailable in our copy. (LLM, conf=0.88)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Following the TGN1412 incident, we developed new pre-clinical in vitro procedures using human PBMCs which can be applied to therapeutic mAbs during development, in order to prevent a repeat of the TGN1412 incident (Stebbings et al., 2007;Findlay et al., 2010).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Discussion
What the sources say
- Supportedcites Stebbings et al., 2007 source
The paper describes developing novel cell-based procedures to improve preclinical safety testing (introductory section) and specifies protocols using human PBMCs (Cytokine release studies using PBMC and whole blood). It says the procedures would have predicted TGN1412’s toxicity and were being applied to emerging immunotherapeutics (opening section), supporting the stated aim of avoiding a repeat incident. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites Findlay et al., 2010 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because macaque T-cells do not secrete IL-2 when stimulated with TGN1412 (Stebbings et al., 2007), it could be speculated that production of IL-2 by stimulated CD4 + effector memory T-cells is a missing factor required for in vitro lymphoproliferative responses by macaque CD4 + memory T-cells.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Supportedcites Stebbings et al., 2007 source
The “Dose responses to TGN1412” section reports that three-day culture supernatants from cynomolgus macaque lymphocytes stimulated with immobilized TGN1412 were negative for IL-2 by ELISA. It detected very low levels of intracellular IL-2-positive cells after six hours, but that does not contradict the claim about secretion. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Second, we show that the new in vitro safety procedures are applicable to other therapeutic mAbs if interleukin (IL)-2 and interferon (IFN)-g are used as key markers for a TGN1412-type response.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
boostedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In vitro IL-2 and IFN-g release from CD4+ effector memory T-cells were key indicators of a TGN1412-type response.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“First, we demonstrate that the cytokine release syndrome stimulated by TGN1412 is not mediated by the same mechanism(s) as those underlying adverse reactions to other therapeutic mAbs (e.g.Campath-1H and Mabthera).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, TNF-a and IL-8 responses were less discriminatory as substantial release was seen with TGN1412, Mabthera and Campath-1H.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
- Not yet classified. 3
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Subsequent analysis of the TGN1412 used at the trial showed that it was formulated correctly, complied with its product specification and was free from pro-inflammatory contaminants (Duff, 2006;Stebbings et al., 2007).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
What the sources say
- Not matchedcites Duff, 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites Stebbings et al., 2007 sourceExperimental — accuracy not yet measured
The introductory section (page not available) says TGN1412 used in the trial tested negative for endotoxin and describes subsequent analysis at NIBSC. The passages available from our copy do not establish that the trial material was correctly formulated, met its product specification, or was free of all pro-inflammatory contaminants; a negative endotoxin test supports only the narrower contamination claim. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“TGN1412 was called a 'superagonist' because it could activate T-cells without the need for prior engagement of the T-cell receptor complex (Tacke et al., 1997;Lühder et al., 2003).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
What the sources say
- Not checked — no full text of the sourcecites Tacke et al., 1997 source
- Partly supportedcites Lühder et al., 2003 sourceExperimental — accuracy not yet measured
The Introduction defines anti-CD28 superagonists as antibodies that fully activate resting T cells without TCR signaling, and the Figure 4 caption describes human T-cell stimulation without TCR triggering. Our copy does not identify TGN1412, so it supports the reason for the label but not the claim about that specific antibody. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Significantly, PBMCs from cynomolgus macaques were not stimulated in vitro by immobilized TGN1412 in agreement with the failure of in vivo administration at any dose tested to evoke any adverse response (Duff, 2006;Stebbings et al., 2007).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
What the sources say
- Not matchedcites Duff, 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites Stebbings et al., 2007 sourceExperimental — accuracy not yet measured
The Lymphocyte proliferation section reports very little proliferation of cynomolgus macaque lymphocytes with immobilized TGN1412, and the Discussion says all tested in vivo doses were well tolerated. But the Activation and intracellular cytokine staining section reports significant up-regulation of an activation marker in macaque T cells. Thus, saying the cells were not stimulated at all overstates the in vitro finding. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This is because we and others (Pitcher et al., 2002;Moniuszko et al., 2004) have shown that cynomolgus and rhesus macaque CD4 + effector memory T-cells do not express CD28; therefore, they cannot be stimulated by CD28 superagonists including TGN1412.”
- Also stated in: § Figure 6 · plain
“In contrast, both cynomolgus and rhesus effector memory T-cells (CCR7 -CD28 -) do not express CD28.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Pitcher et al., 2002 source
- Partly supportedcites Moniuszko et al., 2004 sourceExperimental — accuracy not yet measured
The Results (page unavailable) describe effector memory T cells in Indian rhesus macaques as CD28-low or CD28-negative, supporting the CD28-expression point only in qualified form. The cited paper does not establish that all CD4+ effector memory T cells in both rhesus and cynomolgus macaques lack CD28, or test whether they can be stimulated by CD28 superagonists such as TGN1412. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Figure 6 · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“When we investigated other therapeutic mAbs, known to be capable of causing adverse reactions, Mabthera and Campath-1H (Wing et al., 1995;Chung, 2008), using our new in vitro procedures, we did not detect lymphoproliferative responses or IL-2 release, the cardinal features of TGN1412 stimulation (Stebbings et al., 2007).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Discussion
What the sources say
- Supportedcites Stebbings et al., 2007 source
The citation is attached to the description of lymphoproliferation and IL-2 release as features of TGN1412 stimulation, not to the citing authors’ results for Mabthera and Campath-1H. The source’s “Lymphocyte proliferation” and “Activation and intracellular cytokine staining” sections report both responses in human lymphocytes stimulated with immobilized TGN1412. Page numbers are not provided in our copy. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, peripheral blood contains just 2-5% of all lymphocytes, while the lungs and gastrointestinal mucosa harbour up to 90% of the body's lymphocytes (Cerf-Bensussan and Guy-Grand, 1991;Smit-McBride et al., 1998).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Cerf-Bensussan and Guy-Grand, 1991 source
- Partly supportedcites Smit-McBride et al., 1998 sourceExperimental — accuracy not yet measured
The Abstract states that peripheral blood contains 2–5% of total lymphocytes and that the gastrointestinal tract harbors over 90%. It does not mention the lungs, and its figure is “over 90%,” rather than “up to 90%.” (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Central memory CD4 + T-cells are characterized by strong lymphoproliferative responses (Sallusto et al., 1999;2004), which TGN1412 stimulates from human, but not macaque PBMCs (Stebbings et al., 2007).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Sallusto et al., 1999 source
- Not matchedcites [2004]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Stebbings et al., 2007 source
The Stebbings citation is attached to the human-versus-macaque response, not the preceding characterization of central memory T cells. The Lymphocyte proliferation section reports pronounced proliferation of human lymphocytes with immobilized TGN1412, but very little proliferation of cynomolgus macaque lymphocytes under the same condition. It notes that macaque cells did proliferate when IL-2 was added. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This notion is also consistent with the known capability of CD4 + T-cell subsets to produce cytokines (i.e.naive and central memory CD4 + T-cell subsets both have limited potential for cytokine expression, whereas the effector memory subset has a considerable capability for cytokine production, with IL-2 being a major component of this) (Sallusto et al., 1999;Amyes et al., 2005).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Sallusto et al., 1999 source
- Supportedcites Amyes et al., 2005 source
The section on cytokine-expression capacity reports limited expression in the CCR7-positive subsets, which include naive and central memory cells. It also reports good cytokine-expression capacity in CCR7-negative subsets and says IL-2 expression was most common in subset IIIa, supporting the claim about effector memory cells. Page numbers are unavailable in our copy. (LLM, conf=0.91)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All human CD4 + T-cell memory subsets (naive, central and effector) expressed high levels of CD28 with the effector memory subset defined by a lack of CCR7 expression (Sallusto et al., 1999;2004; Figure 6A).”
- Also stated in: § CD28 is expressed by human, but not macaque, CD4 + effector memory T-cells · plain
“However, we found that the CD4 + effector memory T-cell subsets of both cynomolgus and rhesus macaques did not express CD28, as previously reported for rhesus macaques (Pitcher et al., 2002;Moniuszko et al., 2004; Figure 6A).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > CD28 is expressed by human, but not macaque, CD4 + effector memory T-cells
What the sources say
- Not checked — no full text of the sourcecites Pitcher et al., 2002 source
- Partly supportedcites Moniuszko et al., 2004 sourceExperimental — accuracy not yet measured
The Results (page unavailable) characterize rhesus macaque CD4+ effector memory T cells as CD28-low or CD28-negative, supporting only the rhesus portion in qualified form. The copy does not establish CD28 expression in human effector memory T cells or the claimed CD28 status of cynomolgus CD4+ effector memory T cells; it also does not say all rhesus cells lack CD28. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § CD28 is expressed by human, but not macaque, CD4 + effector memory T-cells · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, it has been previously published that ANC28.1 induces greater or similar in vitro cytokine release than TGN1412 (Waibler et al., 2008), which is in contrast to our findings here that TGN1412 is far more potent than ANC28.1.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Supportedcites Waibler et al., 2008 source
The Results section on in vitro cytokine production reports higher TNF-α, IFN-γ, IL-2, and IL-4 with ANC28.1 than with TGN1412 at the tested concentration. It also reports an exception: TGN1412 induced more IL-10. The citing authors’ contrasting finding is their own, not a finding attributed to Waibler et al. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, we previously reported that immobilized TGN1412 primed macaque CD4 + T-cells and that they underwent marked lymphoproliferation only when exogenous IL-2 was added (Stebbings et al., 2007).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Partly supportedcites Stebbings et al., 2007 sourceExperimental — accuracy not yet measured
The Activation and intracellular cytokine staining section reports that immobilized TGN1412 activated macaque CD4+ T cells without inducing proliferation. The Lymphocyte proliferation section reports proliferation after recombinant IL-2 was added, but says that response was only about 10% of the human response or the macaque mitogen response; calling it “marked” overstates the finding. (LLM, conf=0.87)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This mechanism of cytokine release differed from that of other therapeutic mAbs, which can cause adverse reactions, because these other mAbs stimulate cytokine release primarily from natural killer cells.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast to humans, CD28 is not expressed on the CD4+ effector memory T-cells of all species used for pre-clinical safety testing, so cannot be stimulated by TGN1412.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, other therapeutic mAbs that we tested only stimulated CD4 -lymphocyte cytokine release that comprised high levels of TNF-a, but very low levels of IFN-g and no IL-2.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Initial data showed that human CD4 + CD45RO + memory T-cells were the predominant source of cytokines following TGN1412 stimulation, but this did not explain why in vitro IFN-g levels were low when compared with TNF-a levels.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“As for human cells, we found that both cynomolgus and rhesus macaque CD4 + effector memory T-cells lack CCR7 expression; however, a population of CD28 + CCR7 -were noted that have previously been described as a transitional central memory subset in rhesus macaques (Picker et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > CD28 is expressed by human, but not macaque, CD4 + effector memory T-cells
What the sources say
- Not matchedcites Picker et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, TGN1412 stimulated a large increase in the frequency of IL-2producing lymphocytes of which the majority were CD4 + (Figure 3A; data from two representative donors) and a small proportion were CD4 -, from the same two representative donors (Figure 3A).”
- Also stated in: § Cytokine release from CD4 + T-cells is characteristic of a TGN1412-type response · plain
“In contrast, stimulation with Mabthera or Campath-1H stimulated increases in the frequency of CD4 -, but not CD4 + TNF-aproducing lymphocytes (Figure 3B).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Cytokine release from CD4 + T-cells is characteristic of a TGN1412-type response
plaindirectn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Cytokine release from CD4 + T-cells is characteristic of a TGN1412-type response · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substantial quantities of IFN-g were detected in culture supernatants following 24 h in vitro stimulation with immobilized TGN1412 and much more after 48 and 72 h (Figure 2B).”
- Also stated in: § Substantial IL-2 and IFN-g release is characteristic of a TGN1412-type response · plain
“Substantial concentrations of IL-2 were detected in culture supernatants following 24 h in vitro stimulation with immobilized TGN1412, and these decreased at 48 and 72 h (Figure 2C).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Substantial IL-2 and IFN-g release is characteristic of a TGN1412-type response
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Also stated in: § Substantial IL-2 and IFN-g release is characteristic of a TGN1412-type response · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, the expression of IL-2 following in vitro TGN1412 stimulation showed similar kinetics to its appearance in humans, but the concentrations in cell supernatants were lower than expected.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In marked contrast, PBMCs enriched for CD4 + effector memory T-cells produced high levels of TNF-a, IL-2 and IFN-g, when stimulated with TGN1412, with a large proportion of cells simultaneously producing all three cytokines.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Suntharalingam et al., 2006 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“TGN1412-mediated cytokine release predominantly originated from CD4 + memory T-cells, which produced high levels of TNF-a, IL-2 and IFN-g.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cytokine gene expression that showed the greatest increase following TGN1412 stimulation was TNF-a, followed by IL-2 and then IFN-g (data not shown).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > TGN1412 stimulates rapid cytokine expression in vitro
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within 90 min, both immobilized TGN1412 and Fc-immobilized TGN1412 stimulated significant increases (above those seen with the control antibody) in the frequency of IL-2-producing lymphocytes (both P < 0.0001; Figure 1C).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > TGN1412 stimulates rapid cytokine expression in vitro
Not yet classified.
None of the sources cited for this claim have been checked yet.
In the paper
“In contrast, the CD4 + effector memory T-cells of humans express high levels of CD28 on their surface (Sallusto et al., 1999;2004), so therefore can be stimulated by TGN1412.”
- Also stated in: § Figure 6
“Human, cynomolgus and rhesus macaque naive CD4 + T-cells (CCR7 + CD28 + ) and central memory T-cells (CCR7 + CD28 + ), macaque transitional memory T-cells (CCR7 -CD28 + ) and human effector memory CD4 + T-cells (CCR7 -CD28 + ) all express CD28.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Sallusto et al., 1999 source
- Not matchedcites [2004]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Not yet classified.
- Also stated in: § Figure 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increased levels of TNF-a gene expression were detected 30 min after stimulation with TGN1412, and increased IL-2 and IFN-g gene expression at 60 min.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > TGN1412 stimulates rapid cytokine expression in vitro
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Human CD4 + T-cells constitutively express CD28, so IFN-g staining stems only from the CD28 + population.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, it should be noted that macaque T-cells are not 'less responsive' to in vitro stimulation with TGN1412, but 'non-responsive'.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Macaque CD4 + T-cells can be subdivided into CD28 + (naive, central and transitional memory T-cell) and CD28 -(effector memory T-cell) populations, both of which produce IFN-g following PMA and ionomycin stimulation for 4 h.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, ANC28.1 is a superagonist in vitro in both aqueous phase and when immobilized, whereas we found that TGN1412 was only a superagonist when immobilized.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
- Also stated in: § Introduction · plain
“A near-fatal systemic inflammatory immune response, termed a 'cytokine storm', began 1 h after infusion of TGN1412 in all six healthy recipients, and all became critically ill within 12-16 h (Suntharalingam et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Abstract
What the sources say
- Not checked — no full text of the sourcecites Suntharalingam et al., 2006 source
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Introduction · plain
In the paper
“TGN1412 is a superagonist CD28-specific monoclonal antibody (mAb) developed as an immunotherapeutic for the purpose of balancing the immune system (TeGenero, 2005).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Introduction
What the sources say
- Not matchedcites TeGenero, 2005
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we have identified a species difference almost certainly responsible for this disparate immunopharmacology.”
- Also stated in: § Introduction · hedged
“Third, we identify a species difference in CD28 expression on the CD4 + effector memory T-cell subset as being most likely responsible for the failure of pre-clinical safety testing of TGN1412 in cynomolgus macaques.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Abstract
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: No unequivocal explanation for the failure of TGN1412 to stimulate profound cytokine release in vitro or in vivo in species used for pre-clinical safety testing has been established.
- Also stated in: § Introduction · hedged
In the paper
“However, macaque CD4 + transitional memory T-cells are functionally different to macaque CD4 + effector memory T-cells; IL-2 preferentially induces macaque transitional memory T-cells to proliferate, whereas macaque effector memory T-cells are poorly responsive and vice versa for IL-15 (Picker et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not matchedcites Picker et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, it should be noted that immobilizing mAb to a plastic surface is a highly artificial means of stimulation that is unlikely to simulate what is happening inside the body.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Suntharalingam et al., 2006 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If the explanation were as simple as differences in cell numbers, then all cytokine responses would have been equally lower, but they were not.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“We also did not understand why TGN1412 bound to human and macaque CD28 with equal affinity (TeGenero, 2005), yet caused a 'cytokine storm' only in humans.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Discussion
What the sources say
- Not matchedcites TeGenero, 2005
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within blood, multiple cell types and their subsets can release different cytokines with overlapping repertoires which are not discriminated by ELISA assessment of culture supernatants from mixed cell populations stimulated with mAbs, whereas phenotypic analysis of cytokine-producing cells using flow cytometry, as is shown here, has allowed the dissection of different effector mechanisms.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similar to human CD4 + effector memory T-cells, macaque CD4 + transitional memory T-cells lack CCR7 expression and express CD28 (Picker et al., 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not matchedcites Picker et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
None of the sources cited for this claim have been checked yet.
In the paper
“The lymph nodes and tonsils are enriched in central memory CD4 + T-cells, whereas the lungs and gastrointestinal mucosa contain mainly effector memory CD4 + T-cells (Campbell et al., 2001;Picker, 2006).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Campbell et al., 2001 source
- Not matchedcites Picker, 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Not yet classified.
In the paper
“The evolutionary reason for this subtle comparative immunological difference in receptor expression is unclear, but retention of CD28 expression on human CD4+ effector T-cells would allow the required co-stimulatory signals to reduce activation thresholds (Fraser et al., 1991).”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
What the sources say
- Not checked — no full text of the sourcecites Fraser et al., 1991 source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This difference not only questioned the suitability and validity of existing pre-clinical non-human primate models for the safety testing of therapeutic mAbs, but also for other immunomodulatory biological agents.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, it is likely that ANC28.1 binds to a different region of CD28 from that binding TGN1412, which may explain why lower responses were observed.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While much of the immunopharmacology of cytokine release syndrome in humans remains largely unknown, pre-clinical safety testing in non-human primate models will still be useful, but needs to be interpreted in conjunction with subtleties in antigen expression on target cells in pre-clinical models.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, ANC28.1 does stimulate release of the same pattern of cytokines as TGN1412 so is likely to activate the same pro-inflammatory pathways.”
§ Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cellsb ph_922 512..526 > Figure 6
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
No unequivocal explanation for the failure of TGN1412 to stimulate profound cytokine release in vitro or in vivo in species used for pre-clinical safety testing has been established.
“To date, no unequivocal explanation for the failure of TGN1412 to stimulate profound cytokine release in vitro or in vivo in species used for pre-clinical safety testing has been established.”
The paper relies on this without support.
The in vitro responses to immobilized TGN1412 reflect the mechanism of the in vivo cytokine storm in humans.
“To determine if in vitro stimulation with immobilized TGN1412 (Stebbings et al., 2007) induces rapid cytokine expression, with kinetics similar to the 'cytokine storm' caused by this mAb in humans, we looked at early responses within the first 6 h following stimulation using intracellular cytokine staining and RT-PCR for cytokine mRNAs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rather, IL-2 release and lymphoproliferation are optimal readouts of a TGN1412-like pro-inflammatory response.”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High concentrations (> 5000 pg/ml) of the cytokines TNFα, IL-2, and IFNγ were measured in the plasma of trial volunteers within 4 h of TGN1412 infusion (Suntharalingam et al., 2006).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequently, both interferon (IFN)-γ and IL-2 were found to be better predictive markers of a TGN1412-like cytokine release using immobilized mAbs (Eastwood et al., 2010).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TGN1412 (Section 7.2) is a target- and immune-mediated failure, in which receptor biology rather than pharmacokinetics governed the outcome and which only MABEL-anchored dosing could have contained.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The 2006 TGN1412 phase I trial produced life-threatening cytokine storm in all six healthy volunteers at a dose 500-fold below the no-observed-adverse-effect level (NOAEL) in cynomolgus monkeys.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [72]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The non-predictive result obtained from pre-clinical safety testing in cynomolgus macaques has now been attributed to a lack of CD28 expression on CD4+ effector memory T-cells that therefore cannot be stimulated by TGN1412.”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, high levels of CD28 are expressed on human CD4+ effector memory T-cells, the source of most TGN1412-stimulated pro-inflammatory cytokines.”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“It has emerged that the mechanism of pro-inflammatory cytokine release stimulated by TGN1412 is different to that of other therapeutic mAbs, such that standard pro-inflammatory markers such as TNFα and IL-8 are not discriminatory.”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“The search for an explanation of this led to the identification of CD4+ effector memory T-cells being the source of TGN1412-stimulated IFNγ release (Eastwood et al., 2010; Figure 5).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“It was established that TGN1412 stimulates CD4+ T-cells to undergo lymphoproliferation and release pro-inflammatory cytokines (Stebbings et al., 2007).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“However, cynomolgus macaques were the wrong species for pre-clinical safety testing of TGN1412 because the CD4+ effector memory sub-set of this species does not express CD28 and, therefore, cannot be stimulated by anti-CD28 agonists (Eastwood et al., 2010; Figure 1).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“This result does not correlate well with the severity of the response to TGN1412 compared to Campath-1H and Rituximab, so TNFα and IL-8 release are poorly predictive of the severity of response (Eastwood et al., 2010).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Eastwood et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“the choice of animal model chosen for pre-clinical safety testing of TGN1412, cynomolgus macaques, had been inappropriate because the CD4+ effector memory T-cell subset of this species does not express CD28 and, therefore, cannot be stimulated by CD28 agonists 5 .”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast the CD4+ effector memory T-cell subset of man expresses high levels of CD28 and, therefore, can be stimulated by TGN1412, causing rapid release of high levels of pro-inflammatory cytokines 5 .”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“The failure stemmed from fundamental immunological differences: the distribution of the CD28 receptor on effector memory T cells in humans versus non-human primates produced a qualitatively different pharmacological response [54,71,72].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [72]
In the citing paper
“they found that cynomolgus macaque, but not human, CD4EM cells down-regulate the CD28 molecule and hence cannot be addressed by the CD28SA.”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [47]
In the citing paper
“the cell type we [45] and the Stebbings group [47] had identified as the source of the multiple toxic cytokines released in response to TAB08, i.e., the mostly tissue-resident CD4 effector memory (CD4EM) cells”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [47]
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 11×
“In contrast, the CD4+ effector memory T-cells of humans express high levels of CD28 on their surface (Sallusto et al., 1999; 2004), so therefore can be stimulated by TGN1412.”
BackgroundMethodInfluentialCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 4×
“One of the most striking features of the TGN1412-mediated ‘cytokine storm’ observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
BackgroundResultInfluentialGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28
Fraser, J. D., Irving, B. A., Crabtree, G. R., & Weiss, A. (1991) · Science · doi:10.1126/science.1846244 · Cited by 641
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/35005534 · Cited by 474
Development and Homeostasis of T Cell Memory in Rhesus Macaque
Pitcher, C. J., Hagen, S. I., Walker, J. M., Lum, R., Mitchell, B. L., Maino, V. C., Axthelm, M. K., & Picker, L. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.29 · Cited by 467
Predictors of major infections in systemic lupus erythematosus
Ruiz‐Irastorza, G., Olivares, N., Ruiz‐Arruza, I., Martínez-Berriotxoa, A., Egurbide, M.-V., & Aguirre, C. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2764 · Cited by 371
Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity
Sallusto, F., & Lanzavecchia, A. (2009) · European Journal of Immunology · doi:10.1002/eji.200939722 · Cited by 348
CCR7 Expression and Memory T Cell Diversity in Humans
Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z., Boisvert, J., Greenberg, H. B., Vierra, M. A., Goodman, S. B., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.877 · Cited by 335
Cited by
Sorted by citations
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 464
“response to TGN1412 was deemed to be due to a lack of CD28 expression on CD4 effector memory T cells in macaques, preventing TGN1412 from activating these cells and inducing cytokine production [66].”
BackgroundBaker, K. F., & Isaacs, J. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 383
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 367
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 323
Delivering safer immunotherapies for cancer
Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 311
“but not humans, explaining the inadequacy of the non-human primate studies [110].”
InfluentialPharmacokinetics and toxicology of therapeutic proteins: Advances and challenges
Vugmeyster, Y. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i4.73 · Cited by 252
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Therapeutic antibodies: Market considerations, disease targets and bioprocessing
Elvin, J. G., Couston, R. G., & van der Walle, C. F. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.039 · Cited by 251
Targeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 232
A comprehensive atlas of immunological differences between humans, mice, and non-human primates
Bjornson-Hooper, Z. B., Fragiadakis, G. K., Spitzer, M. H., Chen, H., Madhireddy, D., Hu, K., Lundsten, K., McIlwain, D. R., & Nolan, G. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867015 · Cited by 215
“For example, Fialuridine (TGN1412, CD28 superagonist antibody) was initially evaluated in four animal models (mice, rats, dogs, and monkeys), but when administered to humans at just 1/500 of the dose found to be safe in animals, it caused catastrophic organic failure due to differences in CD28 expression between speci…”
BackgroundIs animal research sufficiently evidence based to be a cornerstone of biomedical research?
Pound, P., & Bracken, M. B. (2014) · BMJ · doi:10.1136/bmj.g3387 · Cited by 207
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S. T., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 186
“Furthermore, CD28 expression on cynomolgus memory T cells was very low or absent, and this contributed to the lack of immunostimulatory responses in NHPs 128 .”
BackgroundToo Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 171
Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Romano, J. D., & Tatonetti, N. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00368 · Cited by 183
Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges
Wang, Y. I., Carmona, C., Hickman, J. J., & Shuler, M. L. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201701000 · Cited by 173
Römer, P. S., Berr, S., Avota, E., Na, S.-Y., Battaglia, M., ten Berge, I., Einsele, H., & Hünig, T. (2011) · Blood · doi:10.1182/blood-2010-12-319780 · Cited by 153
Skokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 151
“pdf), and this was attributed to lower CD28 expression in monkeys (47).”
BackgroundTissue chips – innovative tools for drug development and disease modeling
Low, L. A., & Tagle, D. A. (2017) · Lab on a Chip · doi:10.1039/c7lc00462a · Cited by 143
CD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 147
“However, when the human CD28SA TGN1412 was tested in a first-in-human (FIH) trial in 2006, the healthy volunteers experienced a life-threatening cytokine storm,(98) which resulted from the activation of tissue-resident CD4+ effector memory cells.(92,99) This effect had not been anticipated by primate toxicity testing…”
CD28 Negative T Cells: Is Their Loss Our Gain?
Mou, D., Espinosa, J. R., Lo, D. J., & Kirk, A. D. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12937 · Cited by 137
Goyal, G., Prabhala, P., Mahajan, G., Bausk, B., Gilboa, T., Xie, L., Zhai, Y., Lazarovits, R., Mansour, A., Kim, M. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202103241 · Cited by 124
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Na, S., Mracsko, E., Liesz, A., Hünig, T., & Veltkamp, R. (2015) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 108
“a massive cytokine release syndrome in a phase I clinical trial.(30,31) This serious adverse effect was probably caused by the stimulation of effector memory CD4 T-cells.”
BackgroundPD ‐1/ PD ‐L1 inhibitors in haematological malignancies: update 2017
Jelı́nek, T., Mihályová, J., Kaščák, M., Ďuraš, J., & Hájek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Shah, D., Soper, B. W., & Shopland, L. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190379 · Cited by 118
Cytokine release assays: Current practices and future directions
Finco, D., Grimaldi, C., Fort, M., Walker, M., Kiessling, A., Wolf, B., Salcedo, T., Faggioni, R., Schneider, A., Ibraghimov, A., et al. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.009 · Cited by 106
Self-citationRamani, T., Auletta, C. S., Weinstock, D., Mounho-Zamora, B., Ryan, P. C., Salcedo, T. W., & Bannish, G. (2015) · International Journal of Toxicology · doi:10.1177/1091581815584918 · Cited by 103
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102
“domain of CD28, the loss of Siglec-5 expression during human evolution (11, 12), or a different expression pattern of CD28 on a specific T cell subset (13).”
BackgroundAdvanced model systems and tools for basic and translational human immunology
Wagar, L. E., DiFazio, R. M., & Davis, M. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0584-8 · Cited by 104
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
Yuraszeck, T. M., Kasichayanula, S., & Benjamin, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.651 · Cited by 102
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
Waite, J. C., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R. M., Ajithdoss, D. K., Godin, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba2325 · Cited by 100
“Previous reports suggest a lack of clinical predictivity of cytokine release with CD28 superagonist in monkeys due to the absence of CD28 expression on the CD4+ effector memory T cells in monkeys (55).”
BackgroundImmunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 86
Cyclic AMP underpins suppression by regulatory T cells
Bodor, J., Bopp, T., Vaeth, M., Klein, M., Serfling, E., Hünig, T., Becker, C., Schild, H., & Schmitt, E. (2012) · European Journal of Immunology · doi:10.1002/eji.201141578 · Cited by 80
Poirier, N., Mary, C., Dilek, N., Hervouet, J., Minault, D., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04164.x · Cited by 79
“We believe this makes the model relevant to evaluate in vivo immunotoxicity of human CD28 antibodies since it was identified that effector memory T cells, rather than naı̈ve T cells, were the predominant source of proinflammatory cytokine release under TGN1412 stimulation (63).”
BackgroundWang, Y., Zhang, X., Wang, Y., Zhao, W., Li, H., Zhang, L., Li, X., Zhang, T., Zhang, H., Huang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.004 · Cited by 76
After TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“This result does not correlate well with the severity of the response to TGN1412 compared to Campath-1H and Rituximab, so TNFα and IL-8 release are poorly predictive of the severity of response (Eastwood et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationCD28 co-stimulation: novel insights and applications in cancer immunotherapy
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 86
“The potential for T EM cell activation was missed during toxicology studies in macaques because their CD4 + T cells lose CD28 expression during differentiation into T EM cells, whereas human T EM cells express CD28 179 .”
Brennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
Chimpanzees in Biomedical and Behavioral Research
Institute of Medicine and National Research Council (2011) · National Academies Press eBooks · doi:10.17226/13257 · Cited by 131
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Kellner, C., Derer, S., Valerius, T., & Peipp, M. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.036 · Cited by 75
A coalition to heal—the impact of the cardiac microenvironment
Tzahor, E., & Dimmeler, S. (2022) · Science · doi:10.1126/science.abm4443 · Cited by 72
“Treatment with antibodies against CD28 superagonist resulted in an anti-inflammatory cytokine response and Treg activation, leading to efficacious therapy in many rat and mouse disease models (97).”
BackgroundChistiakov, D. A., Sobenin, I. A., & Orekhov, A. N. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.01.014 · Cited by 67
Poirier, N., Blancho, G., Hiance, M., Mary, C., Assche, T. V., Leempoels, J., Ramael, S., Wang, W., Thépenier, V., Braudeau, C., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601538 · Cited by 66
“T cells lose CD28 expression during their differentiation (35).”
BackgroundVessillier, S., Eastwood, D., Fox, B. J., Sathish, J. G., Sethu, S., Dougall, T., Thorpe, S. J., Thorpe, R., & Stebbings, R. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.04.020 · Cited by 69
“Methods (2015), http://dx.doi.o PBMC SP CRAswere performed bywet coatingwells ofmicrotitre plates at a mAb concentration of 1 μg well−1 for 1 h, followed by washing to remove unboundmAb and then the addition of PBMC for 48 h, as previously described (Eastwood et al., 2010, 2013).”
BackgroundMethodInfluentialSelf-citationYe, C., Yang, H., Cheng, M., Shultz, L. D., Greiner, D. L., Brehm, M. A., & Keck, J. (2020) · The FASEB Journal · doi:10.1096/fj.202001203r · Cited by 60
Animal Models in Translational Research: Rosetta Stone or Stumbling Block?
Bolker, J. A. (2017) · BioEssays · doi:10.1002/bies.201700089 · Cited by 68
Jiménez, S. A., & Piera-Velázquez, S. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.04.004 · Cited by 61
The Model Organism Dictyostelium discoideum
Bozzaro, S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-302-2_2 · Cited by 59
Self-contained, low-cost Body-on-a-Chip systems for drug development
Wang, Y. I., Oleaga, C., Long, C. J., Esch, M. B., McAleer, C. W., Miller, P. G., Hickman, J. J., & Shuler, M. L. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217694101 · Cited by 59
“Animal models, on the other hand, are costly, raise ethical issues, and have shown poor predictive power for human response to drugs due to cross-species discrepancies.(3,4) Alternative models that can improve the accuracy of preclinical evaluation of drug candidates would reduce drug attrition rates during clinical s…”
BackgroundSeverity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
Self-citationUpregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 55
“Later evaluations revealed that macaques lackCD28 on effectormemory T cells and sowere unable to respond.(5) In addition, further species differences were observed in rodent models in which CD28 superagonist mAbs had been found to preferentially activate regulatory T cells.”
BackgroundA Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety
Suchard, S. J., Davis, P. M., Kansal, S., Stetsko, D. K., Brosius, R., Tamura, J. K., Schneeweis, L. A., Bryson, J. W., Salcedo, T. W., Wang, H., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300470 · Cited by 55
“Since the TGN1412 clinical incident, the limitation associated with using cynomolgus macaques for evaluation of TGN1412 toxicity has been attributed to a lack of CD28 expression on CD4 effector memory T cells of this species, whereas high levels of CD28 are expressed on human CD4 effector memory T cells, the source of…”
Backgroundvan Meer, P. J. K., Graham, M. L., & Schuurman, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.055 · Cited by 54
“CD28 shows a differential lack of expression on CD4-positive effector T-memory cells in NHPs that were used in preclinical testing, and this likely played a key role in underestimating the effect and false-negative response, and underestimate the risk (Eastwood et al., 2010).”
BackgroundBiosimilars entering the clinic without animal studies
van Aerts, L., Smet, K. D., Reichmann, G., van der Laan, J. W., & Schneider, C. K. (2014) · mAbs · doi:10.4161/mabs.29848 · Cited by 56
“, in certain oncology conditions where lymphocytes are targeted, or as a result of human-specific response due to differences in T-cell reactivity to a drug, as was the case in the TGN1412 event.(18,19) Infusion reactions, which are also associated with the release of cytokines, may be triggered by different causes, i…”
BackgroundT cell costimulation, checkpoint inhibitors and anti-tumor therapy
Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 58
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 50
Cauvin, A. J., Peters, C., & Brennan, F. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00019-6 · Cited by 60
“The life-threatening cytokine storm effects induced by TGN1412 were a result of the unexpected TGN1412-mediated activation (proliferation and cytokine release) of CD28-expressing CD4+CD45RO+ effector memory T cells predominantly residing in tissue [47].”
BackgroundWolf, B., Morgan, H., Krieg, J., Gani, Z., Milicov, A., Warncke, M., Brennan, F. R., Jones, S., Sims, J., & Kießling, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.018 · Cited by 50
Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer
Bullock, T. N. J. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.02.001 · Cited by 50
Response to 'Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial'
Hünig, T. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c2 · Cited by 48
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 48
“A study showed that TGN1412 induces calcium responses in human naive and memory CD4+ T lymphocytes but not in monkey T lymphocytes (27), which could be explained by a lack of CD28 expression by CD4 effector memory cells in macaques (28).”
BackgroundCancer Models on Chip: Paving the Way to Large‐Scale Trial Applications
Gil, J. F., Moura, C. S., Silvério, V., Gonçalves, G., & Santos, H. A. (2023) · Advanced Materials · doi:10.1002/adma.202300692 · Cited by 45
Primate testing of TGN1412: right target, wrong cell
Pallardy, M. J., & Hünig, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00925.x · Cited by 45
“However, as shown by Eastwood et al. (2010), for TGN1412 it was not a problem of dose calculation, it was simply the fact that hazard identification cannot be done using monkeys, a fact not predictable for investigators and regulators alike, during preclinical development at the time.”
BackgroundShi, R., Honczarenko, M., Zhang, S. X., Fleener, C., Mora, J. R., Lee, S. K., Wang, R., Liu, X., Shevell, D. E., Yang, Z., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.791 · Cited by 44
“0-120) 197 840 (14) 234 288 (8) c 132 (13.”
Glinos, D. A., Soskic, B., Williams, C., Kennedy, A., Jostins, L., Sansom, D. M., & Trynka, G. (2020) · Genes and Immunity · doi:10.1038/s41435-020-00118-0 · Cited by 47
“Since previous studies have shown that CD28 superagonist antibodies can trigger memory T-cell responses in vivo [22, 23], we also investigated how crosslinking CD3 and CD28 antibodies affected naive and memory T-cell responses.”
ResultDhir, V., Fort, M. M., Mahmood, A., Higbee, R. G., Warren, W., Narayanan, P. K., & Wittman, V. (2011) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.613419 · Cited by 44
“Campath-1H and Herceptin have been shown to induce inflammatory cytokines from human WB or PBMC under some experimental conditions (Wing et al., 1995; Eastwood et al., 2010; Findlay et al., 2010).”
BackgroundMethodResultInfluentialSam, J., Höfer, T., Kuettel, C., Claus, C., Thom, J. T., Herter, S., Georges, G. J., Korfi, K., Lechmann, M., Eigenmann, M. J., et al. (2024) · Blood · doi:10.1182/blood.2023023381 · Cited by 42
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 43
“Interestingly, macaque but not human CD4 T cells lose CD28 expression during their differentiation into TEM cells [25].”
BackgroundBartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40
“Although meanwhile it is clear that the nonhuman primate studies were misleading owing to subtle species differences of CD28 expression on T cell subsets (11), until today it is not fully understood why the in vivo potential of TGN1412 to induce massively deregulated cytokine responses was not detected during the prec…”
BackgroundModeling human immune responses to vaccination in vitro
Morrocchi, E., van Haren, S. D., Palma, P., & Levy, O. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.002 · Cited by 40
Costimulation Blockade in Kidney Transplant Recipients
van der Zwan, M., Hesselink, D. A., van den Hoogen, M. W. F., & Baan, C. C. (2019) · Drugs · doi:10.1007/s40265-019-01226-6 · Cited by 39
Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs
Withers, S. S., Moore, P. F., Chang, H., Choi, J. W., McSorley, S. J., Kent, M. S., Monjazeb, A. M., Canter, R. J., Murphy, W. J., Sparger, E. E., et al. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.05.022 · Cited by 43
“that show CD28 expression on T cells in dogs more closely mirrors that of humans, in which CD28 expression is retained by effector memory T cells and potentially only lost in the final stages of T cell differentiation (Eastwood et al., 2010; Rosinski et al., 2015).”
Henry, K. A., Tanha, J., & Hussack, G. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv039 · Cited by 36
The Cynomolgus Macaque MHC Polymorphism in Experimental Medicine
Shiina, T., & Blancher, A. (2019) · Cells · doi:10.3390/cells8090978 · Cited by 35
“The example of the CD28 superagonist monoclonal antibody (TGN1412) is a paradigm of the dangers of extrapolating observations made in the macaque model to humans [19].”
Nabhan, M., Pallardy, M. J., & Turbica, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00725 · Cited by 35
A snapshot of biologic drug development
Andrews, L., Ralston, S. L., Blomme, E. A. G., & Barnhart, K. F. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115603594 · Cited by 37
Ehret, T., Torelli, F., Klotz, C., Pedersen, A. B., & Seeber, F. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00238 · Cited by 32
“Consequently, when TGN1412 was later given to non-laboratory "dirty" mammals (including rodents, see section Getting the Rodent Model "Dirty") exposed to prior environmental microbial stimuli, they experienced similar syndromes as the human volunteers (Eastwood et al., 2010) .”
BackgroundInfluentialA non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 35
Leach, M. W., Clarke, D. O., Dudal, S., Han, C., Li, C., Yang, Z., Brennan, F. R., Bailey, W. J., Chen, Y., Deslandes, A., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2009 · Cited by 36
“Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.”
BackgroundInfluentialBone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome
Yan, H. H., Semple, K. M., Gonzaléz, C. M., & Howard, K. E. (2019) · Translational research · doi:10.1016/j.trsl.2019.04.007 · Cited by 33
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Findlay, L., Eastwood, D., Ball, C., Robinson, C. J., Bird, C., Wadhwa, M., Thorpe, S. J., Thorpe, R., Stebbings, R., & Poole, S. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.06.022 · Cited by 31
“The humanised IgG4κ antibody used as an isotype-matched control for TGN1412 in previous studies (Eastwood et al., 2010; Findlay et al., 2010, 2011 and Stebbings et al., 2007) was included as a control antibody in the present study for continuity with these previous studies.”
BackgroundResultInfluentialSelf-citationIgG Fc variant cross-reactivity between human and rhesus macaque FcγRs
Boesch, A. W., Miles, A., Chan, Y. N., Osei‐Owusu, N. Y., & Ackerman, M. E. (2017) · mAbs · doi:10.1080/19420862.2016.1274845 · Cited by 33
The road (not) taken – Placental transfer and interspecies differences
Schmidt, A., Schmidt, A., & Markert, U. R. (2021) · Placenta · doi:10.1016/j.placenta.2021.09.011 · Cited by 30
Kojima, M., Suzuki, K., Takeshita, M., Ohyagi, M., Iizuka, M., Yamane, H., Koga, K., Kouro, T., Kassai, Y., Yoshihara, T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04874-3 · Cited by 31
Schmidt, T., Willenborg, S., Hünig, T., Deeg, C. A., Sønderstrup, G., Hertl, M., & Eming, R. (2015) · Experimental Dermatology · doi:10.1111/exd.12919 · Cited by 30
Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.019 · Cited by 29
“have identified CD4CD45RO effector memory T cells as the predominant source of in vitro TNFa, IL-2 and IFNc release, with only a small proportion of cytokine production from CD4 cells, following stimulation by immobilised TGN1412 [10].”
BackgroundMethodResultInfluentialSelf-citationVandivort, T. C., Horton, D. B., & Johnson, S. B. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.493 · Cited by 28
Lin, Z., Huang, Y., Jiang, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4548 · Cited by 28
“Eastwood et al. found that the failure of the monoclonal antibody TGN1412 trial was due to species differences in CD28 expression on CD4+ effector memory T cells (34).”
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
de Olza, M. O., Oliva, M., Hierro, C., Matos, I. G., Martín-Liberal, J., & Garralda, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy225 · Cited by 28
Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 27
Immune checkpoints in sepsis: New hopes and challenges
Liu, Y., Shou, S., & Chai, Y. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884247 · Cited by 27
“A later study confirmed that the cytokines storm was related to the activation of CD4+ effector memory T cells (TEM) and ineffective activation of the regulatory T cells (Tregs) in humans [12].”
BackgroundHumanized Mouse Models for Immuno‐oncology Drug Discovery
Kumari, R., Feuer, G., & Bourré, L. (2023) · Current Protocols · doi:10.1002/cpz1.852 · Cited by 28
“TGN1412 induces lymphopenia and human cytokine release in a humanized mouse model.”
BackgroundInfluentialPoirier, N., Chevalier, M., Mary, C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501810 · Cited by 27
“memory T lymphocytes (Tem) of macaques do not express CD28 (9, 10) and might show different costimulation requirements for their activation than do human and baboon counterparts.”
BackgroundMethodICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Weissmüller, S., Semmler, L. Y., Kalinke, U., Christians, S., Müller-Berghaus, J., & Waibler, Z. (2012) · Blood · doi:10.1182/blood-2011-12-401083 · Cited by 26
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Hérault, A., Mak, J., Cruz-Chuh, J. D., Dillon, M., Ellerman, D. A., Go, M., Cosino, E., Clark, R., Carson, E., Yeung, S., et al. (2024) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-024-03795-2 · Cited by 24
Metadata
- Authors
- Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R.
- Affiliations
- National Institute for Biological Standards and Control (GB)
- Corresponding author
- Stebbings, R
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-09-03
- Volume
- 161
- Issue
- 3
- Pages
- 512-526
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2990151
- OpenAlex
- W1490736032
- Cited by
- 300
- References
- 43
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 18 · 2023: 15 · 2022: 13 · 2021: 16 · 2020: 18 · 2019: 13 · 2018: 20 · 2017: 31 · 2016: 16 · 2015: 19 · 2014: 24 · 2013: 29 · 2012: 27
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGN1412, cytokine storm, CD4+ effector memory T cells, species differences, IL-2 release, IFN-gamma release, T cell activation, immunopharmacology, adverse drug reactions
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Immunologic Memory, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Macaca, Macaca fascicularis, Species Specificity, T-Lymphocytes, CD4-Positive T-Lymphocytes, Cytokines, Clinical Trials, Phase I as Topic, CD28 Antigens, Toxicity Tests, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
